“GLP-1 is projected to be a $100 billion market by 2030, indicating a substantial increase in syringe consumption.” says Cory Lewis, CEO, President, and Founder of INCOG BioPharma Services.
Ahead of CDMO Live this week, Cory spoke to the PharmaSource podcast about why strategic thinking is crucial for success in this fast-moving landscape.
🎧 Listen to the full interview: https://lnkd.in/esj9YYAv
“We’re not just planning for the immediate needs but looking one, two, even three years ahead. With our second and third production lines in the pipeline, we’re preparing for the long-term demands of the market.”
Founded in June 2020, INCOG has secured FDA-approval and now establishes itself as a new force in contract manufacturing with a focus on sterile injectables.
Despite the company only being four years old, INCOG’s leadership team brings decades of industry experience. Cory says he has brought the ‘band back together’ by reuniting seasoned professionals to create a tier-one contract manufacturing organisation.
INCOG’s investments in vial, syringe, and cartridge filling capabilities are “just the beginning” he says.
“We’re also expanding into quality control, lab stability services, and eventually, auto-injector device assembly and final packaging. Our long-term site master plan outlines our ambition to not only enhance filling capacity, but also integrate additional business units to support commercial packaging and device assembly.”
“Our first FDA approval, achieved less than eighteen months after production began, is a testament to our operational and quality excellence. This milestone was marked by an eight-day inspection with zero observations, a rare accomplishment in our industry.”
---
Join INCOG at #CDMOLive this Thursday, for an exclusive online event dedicated to accelerating, optimising and decarbonising contract manufacturing.
👉 Register here for your free ticket: https://lnkd.in/eNB_vxzm
#CDMO #GLP1
Thank you for sharing! Expanding manufacturing capabilities in the U.S. is a strategic move to ensure timely support for shifting seasonal demands.